251 related articles for article (PubMed ID: 19602866)
1. Solitary subungual keratoacanthoma arising in an MSH2 germline mutation carrier: confirmation of a relationship by immunohistochemical analysis.
Stoebner PE; Fabre C; Delfour C; Joujoux JM; Roger P; Dandurand M; Meunier L
Dermatology; 2009; 219(2):174-8. PubMed ID: 19602866
[TBL] [Abstract][Full Text] [Related]
2. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
[TBL] [Abstract][Full Text] [Related]
3. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
4. A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma.
Hirata K; Kanemitsu S; Nakayama Y; Nagata N; Itoh H; Ohnishi H; Ishikawa H; Furukawa Y;
Am J Gastroenterol; 2006 Jan; 101(1):193-6. PubMed ID: 16405554
[TBL] [Abstract][Full Text] [Related]
5. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
6. [Mutation in the MSH2 gene in Muir-Torre syndrome].
Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
[TBL] [Abstract][Full Text] [Related]
7. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
8. A novel missense MSH2 gene mutation in a patient of a Korean family with hereditary nonpolyposis colorectal cancer.
Park SJ; Lee KA; Park TS; Kim NK; Song J; Kim BY; Choi JR
Cancer Genet Cytogenet; 2008 Apr; 182(2):136-9. PubMed ID: 18406877
[TBL] [Abstract][Full Text] [Related]
9. Report on de-novo mutation in the MSH2 gene as a rare event in hereditary nonpolyposis colorectal cancer.
Morak M; Laner A; Scholz M; Madorf T; Holinski-Feder E
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1101-5. PubMed ID: 19047842
[TBL] [Abstract][Full Text] [Related]
10. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
Ponti G; Ponz de Leon M; Losi L; Di Gregorio C; Benatti P; Pedroni M; Scarselli A; Riegler G; Lembo L; Pellacani G; Seidenari S; Rossi G; Roncucci L
Br J Dermatol; 2005 Jun; 152(6):1335-8. PubMed ID: 15949004
[TBL] [Abstract][Full Text] [Related]
11. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.
Stella A; Surdo NC; Lastella P; Barana D; Oliani C; Tibiletti MG; Viel A; Natale C; Piepoli A; Marra G; Guanti G
Clin Genet; 2007 Feb; 71(2):130-9. PubMed ID: 17250661
[TBL] [Abstract][Full Text] [Related]
12. Family with MSH2 mutation presenting with keratoacanthoma and precancerous skin lesions.
Hatta N; Takata A; Ishizawa S; Niida Y
J Dermatol; 2015 Nov; 42(11):1087-90. PubMed ID: 26077460
[TBL] [Abstract][Full Text] [Related]
13. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene.
Banville N; Geraghty R; Fox E; Leahy DT; Green A; Keegan D; Geoghegan J; O'Donoghue D; Hyland J; Sheahan K
Hum Pathol; 2006 Nov; 37(11):1498-502. PubMed ID: 16996571
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer and the Muir-Torre syndrome in a Gypsy family: a review.
Lynch HT; Leibowitz R; Smyrk T; Fusaro RM; Lynch JF; Smith A; Franklin B; Stella A; Liu B
Am J Gastroenterol; 1999 Mar; 94(3):575-80. PubMed ID: 10086635
[TBL] [Abstract][Full Text] [Related]
15. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
[TBL] [Abstract][Full Text] [Related]
16. [Muir-Torre syndrome].
Jonas J; Kruse R; Bähr R
Chirurg; 2002 Apr; 73(4):366-9. PubMed ID: 12063922
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
18. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature.
Nishizawa A; Nakanishi Y; Sasajima Y; Yamazaki N; Yamamoto A
Am J Dermatopathol; 2006 Feb; 28(1):56-9. PubMed ID: 16456327
[TBL] [Abstract][Full Text] [Related]
19. [Muir-Torre syndrome].
Yoshikawa R; Utsunomiya J
Nihon Rinsho; 1995 Nov; 53(11):2803-6. PubMed ID: 8538048
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer.
Ponti G; Losi L; Pellacani G; Wannesson L; Cesinaro AM; Venesio T; Petti C; Seidenari S
Br J Dermatol; 2008 Jul; 159(1):162-8. PubMed ID: 18460031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
